tiprankstipranks
Trending News
More News >
Genfit SA (FR:GNFT)
:GNFT

Genfit (GNFT) AI Stock Analysis

Compare
8 Followers

Top Page

FR

Genfit

(OTC:GNFT)

Rating:55Neutral
Price Target:
€3.50
▲(6.06%Upside)
The overall stock score of 54.65 reflects Genfit's recent financial improvements and operational efficiency. However, high valuation concerns and historical revenue volatility moderate the score. Technical indicators suggest a neutral outlook, with no strong momentum in either direction.

Genfit (GNFT) vs. iShares MSCI France ETF (EWQ)

Genfit Business Overview & Revenue Model

Company DescriptionGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
How the Company Makes MoneyGenfit makes money primarily through the development and commercialization of its therapeutic and diagnostic products. Revenue streams include licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of approved drugs and diagnostics. Significant partnerships with companies and research institutions help advance its pipeline and share costs and profits from successful product commercialization. Additionally, Genfit may receive milestone payments and royalties based on the development and commercialization stages of its partnered products. The company also invests in research and development to continually innovate and expand its product offerings, which can lead to future revenue growth.

Genfit Financial Statement Overview

Summary
Genfit has shown significant improvement in financial performance in 2024, with a return to profitability and stronger cash flows. Effective cost management and operational efficiency are evident, but concerns remain about historical revenue volatility and asset reduction. The financial health is stable with a balanced debt-to-equity ratio, though long-term asset sustainability and profitability need close monitoring.
Income Statement
62
Positive
Genfit experienced a significant recovery in 2024 with a substantial increase in revenue from 2023, resulting in a return to profitability with a net profit margin of 2.25%. The gross profit margin is robust at 99.55%, indicating effective cost management. EBIT and EBITDA margins have improved significantly, reflecting enhanced operational efficiency. However, the revenue growth has been volatile over the years, indicating a lack of stability in sales performance.
Balance Sheet
58
Neutral
The company's financial structure shows a moderate debt-to-equity ratio of 0.90, indicating a balanced use of debt and equity. Return on Equity (ROE) is modest at 2.18%, suggesting limited profitability for shareholders. The equity ratio of 45.73% indicates a healthy balance sheet with adequate equity cushion. However, the substantial decrease in total assets over recent years might pose a risk to long-term asset sustainability.
Cash Flow
68
Positive
Genfit's cash flow position has improved, with a strong free cash flow growth from the previous year and a solid free cash flow to net income ratio of 9.44. The operating cash flow to net income ratio of 10.09 demonstrates effective cash generation from operations. However, the past volatility in operating cash flows might indicate future cash flow uncertainties.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue67.00M28.57M20.20M80.07M765.00K
Gross Profit66.70M28.22M19.95M79.91M563.00K
EBITDA8.35M-22.24M-23.60M34.91M-91.14M
Net Income1.51M-28.89M-23.72M67.26M-101.22M
Balance Sheet
Total Assets151.42M173.87M215.54M281.72M198.61M
Cash, Cash Equivalents and Short-Term Investments81.79M77.79M140.55M258.76M171.03M
Total Debt62.13M70.18M75.28M74.23M185.69M
Total Liabilities82.20M105.92M121.01M162.62M214.78M
Stockholders Equity69.22M67.95M94.53M119.10M-16.16M
Cash Flow
Free Cash Flow14.22M-57.92M-72.64M99.38M-97.27M
Operating Cash Flow15.20M-55.43M-72.64M99.92M-96.37M
Investing Cash Flow-1.04M2.23M-46.27M-3.38M-966.00K
Financing Cash Flow-10.22M-5.10M-3.79M-8.92M-8.26M

Genfit Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.30
Price Trends
50DMA
3.67
Negative
100DMA
3.55
Negative
200DMA
3.89
Negative
Market Momentum
MACD
-0.12
Positive
RSI
30.85
Neutral
STOCH
5.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GNFT, the sentiment is Negative. The current price of 3.3 is below the 20-day moving average (MA) of 3.63, below the 50-day MA of 3.67, and below the 200-day MA of 3.89, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 30.85 is Neutral, neither overbought nor oversold. The STOCH value of 5.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:GNFT.

Genfit Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
$164.86M104.892.17%134.56%
46
Neutral
C$190.36M-4.25-8.56%3.09%13.53%-1.76%
$168.48M-160.99%
€397.17M-148.98%
€210.79M-199.50%
€187.77M
DE6OP
€116.34M2.9486.78%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:GNFT
Genfit
3.30
-0.42
-11.30%
IPHYF
Innate Pharma SA
1.95
-0.17
-8.02%
GB:0RA9
Abivax SA
6.30
-5.36
-45.97%
GB:0QAJ
DBV Technologies
1.53
0.73
91.25%
GB:0QAV
Nanobiotix
3.98
-0.98
-19.76%
DE:6OP
OSE Immunotherapeutics SA
5.08
-0.35
-6.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 14, 2025